Persistent Readiness Through Early Prediction Immunization Study

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

249

Participants

Timeline

Start Date

February 8, 2022

Primary Completion Date

December 21, 2022

Study Completion Date

December 21, 2022

Conditions
Inflammatory Response
Interventions
DRUG

Pneumovax 23

At +14 days from enrollment in the trial, participants will receive a vaccine administered via intramuscular route only.

DRUG

Typhim VI

At +14 days from enrollment in the trial, participants will receive a vaccine administered via intramuscular route only.

OTHER

Saline

At +14 days from enrollment in the trial, participants will receive a vaccine administered via intramuscular route only.

Trial Locations (1)

77845

Texas A&M University - CTRAL, College Station

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Philips Healthcare

INDUSTRY

collaborator

US Department of Defense - Defense Threat Reduction Agency

UNKNOWN

lead

Texas A&M University

OTHER

NCT05346302 - Persistent Readiness Through Early Prediction Immunization Study | Biotech Hunter | Biotech Hunter